Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Adrenocortical Carcinoma | Research

TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma

Authors: Lin Cheng, Tong Han, Bolin Chen, Kechao Nie, Weijun Peng

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Enhancer RNAs (eRNAs) are demonstrated to be closely associated with tumourigenesis and cancer progression. However, the role of eRNAs in lung adenocarcinoma (LUAD) remains largely unclear. Thus, a comprehensive analysis was constructed to identify the key eRNAs, and to explore the clinical utility of the identified eRNAs in LUAD.

Methods

First, LUAD expression profile data from the Cancer Genome Atlas (TCGA) dataset and eRNA-relevant information were integrated for Kaplan-Meier survival analysis and Spearman’s correlation analysis to filtered the key candidate eRNAs that was associated with survival rate and their target genes in LUAD. Then, the key eRNA was selected for subsequent clinical correlation analysis. KEGG pathway enrichment analyses were undertaken to explore the potential signaling pathways of the key eRNA. Data from the human protein atlas (HPA) database were used to validate the outcomes and the quantitative real time-polymerase chain reaction (qRT-PCR) analysis was conducted to measure eRNA expression levels in tumor tissues and paired normal adjacent tissues from LUAD patients. Finally, the eRNAs were validated in pan-cancer.

Results

As a result, TBX5-AS1 was identified as the key eRNA, which has T-box transcription factor 5 (TBX5) as its regulatory target. KEGG analysis indicated that TBX5-AS1 may exert a vital role via the PI3K/AKT pathway, Ras signaling pathway, etc. Additionally, the qRT-PCR results and the HPA database indicated that TBX5-AS1 and TBX5 were significantly downregulated in tumour samples compared to matched-adjacent pairs. The pan-cancer validation results showed that TBX5-AS1 was associated with survival in four tumors, namely, adrenocortical carcinoma (ACC), LUAD, lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC). Correlations were found between TBX5-AS1 and its target gene, TBX5, in 26 tumor types.

Conclusion

Collectively, our results indicated that TBX5-AS1 may be a potential prognostic biomarker for LUAD patients and promote the targeted therapy of LUAD.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Wang L, Yu C, Liu Y, Wang J, Li C, Wang Q, et al. Lung Cancer mortality trends in China from 1988 to 2013: new challenges and opportunities for the government. Int J Environ Res Public Health. 2016;13(11):1052. https://doi.org/10.3390/ijerph13111052.CrossRefPubMedCentral

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. https://doi.org/10.1056/NEJMra0802714.CrossRefPubMed

Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. https://doi.org/10.1038/nature13385.

Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101–8. https://doi.org/10.1038/nature11233.CrossRefPubMedPubMedCentral

Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013;9(6):e1003569. https://doi.org/10.1371/journal.pgen.1003569.CrossRefPubMedPubMedCentral

Lee JH, Xiong F, Li W. Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential. RNA Biol. 2020;17(11):1550–9. https://doi.org/10.1080/15476286.2020.1712895.CrossRefPubMedPubMedCentral

Natoli G, Andrau JC. Noncoding transcription at enhancers: general principles and functional models. Annu Rev Genet. 2012;46(1):1–19. https://doi.org/10.1146/annurev-genet-110711-155459.CrossRefPubMed

Andersson R, Gebhard C, Miguel-Escalada I, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507(7493):455–61. https://doi.org/10.1038/nature12787.CrossRefPubMedPubMedCentral

10.

Li W, Notani D, Rosenfeld MG. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat Rev Genet. 2016;17(4):207–23. https://doi.org/10.1038/nrg.2016.4.CrossRefPubMed

11.

Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Liang H, et al. A pan-Cancer analysis of enhancer expression in nearly 9000 patient samples. Cell. 2018;173(2):386–99. https://doi.org/10.1016/j.cell.2018.03.027.CrossRefPubMedPubMedCentral

12.

Grosschedl R, Birnstiel ML. Spacer DNA sequences upstream of the T-A-T-A-A-A-T-A sequence are essential for promotion of H2A histone gene transcription in vivo. Proc Natl Acad Sci U S A. 1980;77(12):7102–6. https://doi.org/10.1073/pnas.77.12.7102.CrossRefPubMedPubMedCentral

13.

Benoist C, Chambon P. In vivo sequence requirements of the SV40 early promoter region. Nature. 1981;290(5804):304–10. https://doi.org/10.1038/290304a0.CrossRefPubMed

14.

Andersson R. Promoter or enhancer, what’s the difference? Deconstruction of established distinctions and presentation of a unifying model. Bioessays. 2015;37(3):314–23. https://doi.org/10.1002/bies.201400162.CrossRefPubMed

15.

Lam MT, Cho H, Lesch HP, Gosselin D, Heinz S, Tanaka-Oishi Y, et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature. 2013;498(7455):511–5. https://doi.org/10.1038/nature12209.CrossRefPubMedPubMedCentral

16.

Lin YC, Benner C, Mansson R, Heinz S, Miyazaki K, Miyazaki M, et al. Global changes in the nuclear positioning of genes and intra- and interdomain genomic interactions that orchestrate B cell fate. Nat Immunol. 2012;13(12):1196–204. https://doi.org/10.1038/ni.2432.CrossRefPubMedPubMedCentral

17.

Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature. 2012;489(7414):109–13. https://doi.org/10.1038/nature11279.CrossRefPubMedPubMedCentral

18.

Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JAF, et al. eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell. 2013;49(3):524–35. https://doi.org/10.1016/j.molcel.2012.11.021.CrossRefPubMed

19.

Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, et al. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014;111(20):7319–24. https://doi.org/10.1073/pnas.1324151111.CrossRefPubMedPubMedCentral

20.

Bal E, Park HS, Belaid-Choucair Z, Kayserili H, Naville M, Madrange M, et al. Mutations in ACTRT1 and its enhancer RNA elements lead to aberrant activation of hedgehog signaling in inherited and sporadic basal cell carcinomas. Nat Med. 2017;23(10):1226–33. https://doi.org/10.1038/nm.4368.CrossRefPubMed

21.

Tan SH, Leong WZ, Ngoc P, et al. The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia. Blood. 2019;134(3):239–51. https://doi.org/10.1182/blood.2018874503.CrossRefPubMedPubMedCentral

22.

Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, et al. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nat Commun. 2019;10(1):4562. https://doi.org/10.1038/s41467-019-12543-5.CrossRefPubMedPubMedCentral

23.

Gu X, Wang L, Boldrup L, Coates P, Fahraeus R, Sgaramella N, et al. AP001056.1, A Prognosis-Related Enhancer RNA in Squamous Cell Carcinoma of the Head and Neck. Cancers. 2019;11(3):347. https://doi.org/10.3390/cancers11030347.CrossRefPubMedCentral

24.

Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

25.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMedPubMedCentral

26.

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51. https://doi.org/10.1093/nar/gkaa970.CrossRefPubMed

27.

Shih JH, Chen HY, Lin SC, Yeh YC, Shen R, Lang YD, et al. Integrative analyses of noncoding RNAs reveal the potential mechanisms augmenting tumor malignancy in lung adenocarcinoma. Nucleic Acids Res. 2020;48(3):1175–91. https://doi.org/10.1093/nar/gkz1149.CrossRefPubMed

28.

Zhao T, Khadka VS, Deng Y. Identification of lncRNA biomarkers for lung cancer through integrative cross-platform data analyses. Aging (Albany NY). 2020;12(14):14506–27. https://doi.org/10.18632/aging.103496.CrossRef

29.

Qu QH, Jiang SZ, Li XY. LncRNA TBX5-AS1 regulates the tumor progression through the PI3K/AKT pathway in non-small cell lung Cancer. Onco Targets Ther. 2020;13:7949–61. https://doi.org/10.2147/OTT.S255195.CrossRefPubMedPubMedCentral

30.

Schmitt AD, Hu M, Ren B. Genome-wide mapping and analysis of chromosome architecture. Nat Rev Mol Cell Biol. 2016;17(12):743–55. https://doi.org/10.1038/nrm.2016.104.CrossRefPubMedPubMedCentral

31.

Li W, Notani D, Ma Q, Tanasa B, Nunez E, Chen AY, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature. 2013;498(7455):516–20. https://doi.org/10.1038/nature12210.CrossRefPubMedPubMedCentral

32.

Jiao W, Chen Y, Song H, Li D, Mei H, Yang F, et al. HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis. Oncogene. 2018;37(20):2728–45. https://doi.org/10.1038/s41388-018-0128-0.CrossRefPubMed

33.

Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24(5):513–31. https://doi.org/10.1038/cr.2014.35.CrossRefPubMedPubMedCentral

34.

Zhu T, Qiao L, Wang Q, Mi R, Chen J, Lu Y, et al. T-box family of transcription factor-TBX5, insights in development and disease. Am J Transl Res. 2017;9(2):442–53.PubMedPubMedCentral

35.

Zhang XL, Qiu XB, Yuan F, et al. TBX5 loss-of-function mutation contributes to familial dilated cardiomyopathy. Biochem Biophys Res Commun. 2015;55:1417–25.

36.

Khan P, Linkhart B, Simon HG. Different regulation of T⁃box genes Tbx4 and Tbx5 during limb development and limb regeneration. Dev Biol. 2002;250(2):383–92. https://doi.org/10.1006/dbio.2002.0801.CrossRefPubMed

37.

Kim J, Siverly AN, Chen D, Wang M, Yuan Y, Wang Y, et al. Ablation of miR-10b suppresses oncogene-induced mammary Tumourigenesis and metastasis and reactivates tumor-suppressive pathways. Cancer Res. 2016;76(21):6424–35. https://doi.org/10.1158/0008-5472.CAN-16-1571.CrossRefPubMedPubMedCentral

38.

Zheng Y, Li Y, Wang W, et al. High expression level of T-box transcription factor 5 predicts unfavorable survival in stage I and II gastric adenocarcinoma. Oncol Lett. 2015;10(4):2021–6. https://doi.org/10.3892/ol.2015.3515.CrossRefPubMedPubMedCentral

39.

Becker J, May A, Gerges C, Anders M, Schmidt C, Veits L, et al. The Barrett⁃associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk. Cancer Med. 2016;5(5):888–91. https://doi.org/10.1002/cam4.641.CrossRefPubMedPubMedCentral

40.

Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett′s esophagus. Gastroenterology. 2015;148(2):367–78. https://doi.org/10.1053/j.gastro.2014.10.041.CrossRefPubMed

41.

Yu J, Ma X, Cheung KF, Li X, Tian L, Wang S, et al. Epigenetic inactivation of T⁃box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene. 2010;29(49):6464–74. https://doi.org/10.1038/onc.2010.370.CrossRefPubMed

42.

Ruoting M, Yu Y, Qiuyun T, et al. Overexpression of T-box transcription factor 5 (TBX5) inhibits proliferation and invasion in non-small cell lung carcinoma cells. Oncol Res. 2017;25:1495–504.CrossRef

Title: TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma
Authors: Lin Cheng
Tong Han
Bolin Chen
Kechao Nie
Weijun Peng
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Adrenocortical Carcinoma
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08517-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer

Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study

Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature

Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis

High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer

Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum

Keynote webinar | Spotlight on antibody–drug conjugates in cancer